Corindus Launches CorPath Robotic-Assisted PCI Program at Massachusetts General Hospital

January 5, 2016—Corindus Vascular Robotics, Inc. announced the launch of a CorPath robotic-assisted percutaneous coronary intervention (PCI) program at Massachusetts General Hospital (MGH) in Boston, Massachusetts, and the installation of the hospital’s first CorPath system. Involvement in the robotic-assisted PCI program will allow physicians at MGH to perform PCI procedures using the CorPath system, while protected from radiation exposure in the system's radiation-shielded control cockpit.

In October, Corindus announced the formation of a joint research and clinical program with the Mayo Clinic in Rochester, Minnesota. 

According to the company, the CorPath system, which is cleared by US Food and Drug Administration, brings robotic-assisted precision to PCI procedures while protecting medical professionals from radiation exposure occurring in hospital catheterization laboratories. 

The CorPath system allows interventional cardiologists to perform procedures while seated in a radiation-protected cockpit just a few feet away from the patient bed side. The physician uses intuitive digital controls to robotically advance guidewires, angioplasty balloons, and stents through coronary arteries. The CorPath system recently received FDA 510(k) clearance for radial-access PCI procedures.

In the company’s announcement, Doug Drachman, MD, Director of MGH’s cardiovascular fellowship program, commented, “Emerging technologies should contribute to the well-being of patients and physicians. Robotic assistance provides enhanced visualization and potentially increased accuracy. Coupled with radiation reduction for clinicians, these advances may not only improve care, but also the long-term health of patient and provider.”